Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 3
2010 3
2011 12
2012 9
2013 16
2014 13
2015 18
2016 15
2017 15
2018 5
2019 3
2020 8
2021 9
2022 14
2023 12
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Results by year

Filters applied: . Clear all
Page 1
Hepatitis A Virus Infection and Molecular Research.
Kanda T, Sasaki-Tanaka R, Nakamoto S. Kanda T, et al. Among authors: nakamoto s. Int J Mol Sci. 2022 Jun 29;23(13):7214. doi: 10.3390/ijms23137214. Int J Mol Sci. 2022. PMID: 35806219 Free PMC article.
A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study.
Kobayashi K, Ogasawara S, Maruta S, Okubo T, Itokawa N, Haga Y, Seko Y, Moriguchi M, Watanabe S, Shiko Y, Takatsuka H, Kanzaki H, Koroki K, Inoue M, Nakamura M, Kiyono S, Kanogawa N, Kondo T, Suzuki E, Ooka Y, Nakamoto S, Inaba Y, Ikeda M, Okabe S, Morimoto N, Itoh Y, Nakamura K, Ito K, Azemoto R, Atsukawa M, Itobayashi E, Kato N. Kobayashi K, et al. Among authors: nakamoto s. Clin Cancer Res. 2023 Dec 1;29(23):4760-4769. doi: 10.1158/1078-0432.CCR-23-1462. Clin Cancer Res. 2023. PMID: 37796614
Hepatitis C virus genotypes in Myanmar.
Win NN, Kanda T, Nakamoto S, Yokosuka O, Shirasawa H. Win NN, et al. Among authors: nakamoto s. World J Gastroenterol. 2016 Jul 21;22(27):6095-9. doi: 10.3748/wjg.v22.i27.6095. World J Gastroenterol. 2016. PMID: 27468202 Free PMC article.
Sofosbuvir treatment and hepatitis C virus infection.
Nakamura M, Kanda T, Haga Y, Sasaki R, Wu S, Nakamoto S, Yasui S, Arai M, Imazeki F, Yokosuka O. Nakamura M, et al. Among authors: nakamoto s. World J Hepatol. 2016 Jan 28;8(3):183-90. doi: 10.4254/wjh.v8.i3.183. World J Hepatol. 2016. PMID: 26839641 Free PMC article. Review.
Changes in therapeutic options for hepatocellular carcinoma in Asia.
Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Ogasawara S, et al. Among authors: nakamoto s. Liver Int. 2022 Aug;42(9):2055-2066. doi: 10.1111/liv.15101. Epub 2021 Nov 29. Liver Int. 2022. PMID: 34780081 Review.
Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma.
Qiang N, Ao J, Nakamura M, Chiba T, Kusakabe Y, Kaneko T, Kurosugi A, Kogure T, Ma Y, Zhang J, Ogawa K, Kan M, Iwanaga T, Sakuma T, Kanayama K, Kanzaki H, Kojima R, Nakagawa R, Kondo T, Nakamoto S, Muroyama R, Kato J, Mimura N, Ma A, Jin J, Kato N. Qiang N, et al. Among authors: nakamoto s. Int Immunopharmacol. 2023 May;118:110068. doi: 10.1016/j.intimp.2023.110068. Epub 2023 Mar 29. Int Immunopharmacol. 2023. PMID: 37001386
Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis.
Kanzaki H, Ogasawara S, Okubo T, Itokawa N, Yoshino R, Fujimoto K, Kogure T, Yumita S, Ishino T, Ogawa K, Iwanaga T, Nakagawa M, Fujiwara K, Kojima R, Koroki K, Inoue M, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Itobayashi E, Atsukawa M, Kato J, Kato N. Kanzaki H, et al. Among authors: nakamoto s. Drugs Real World Outcomes. 2023 Dec;10(4):513-520. doi: 10.1007/s40801-023-00379-x. Epub 2023 Jul 19. Drugs Real World Outcomes. 2023. PMID: 37466822 Free PMC article.
Successful Identification of a Novel Therapeutic Compound for Hepatocellular Carcinoma Through Screening of ADAM9 Inhibitors.
Ogawa K, Chiba T, Nakamura M, Arai J, Zhang J, Ma Y, Qiang NA, Ao J, Yumita S, Ishino T, Kan M, Iwanaga T, Nakagawa M, Fujiwara K, Sakuma T, Kanzaki H, Koroki K, Kusakabe Y, Kobayashi K, Kanogawa N, Kiyono S, Kondo T, Nakagawa R, Ogasawara S, Muroyama R, Nakamoto S, Kanda T, Maruyama H, Kato J, Matsumoto S, Arai T, Motohashi S, Kato N. Ogawa K, et al. Among authors: nakamoto s. Anticancer Res. 2023 Mar;43(3):1043-1052. doi: 10.21873/anticanres.16249. Anticancer Res. 2023. PMID: 36854524
140 results